At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 77 target
Drug / intervention
RC48-ADCdrug
Likely dose
RC48-ADC 2.0 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Phase II Study of RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive High-risk Non-muscle-invasive Bladder Cancer
In Brief
A Phase 2 clinical trial evaluating RC48-ADC for Non-muscle Invasive Bladder Cancer. Not yet recruiting, targeting 77 participants across 1 site.
Detailed Summary
This study will evaluate the efficacy and safety of intravenous RC48-ADC in adjuvant/salvage treatment of HER2 positive high-risk non-muscle-invasive bladder cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-muscle Invasive Bladder Cancer
CountriesChina
CollaboratorsRemeGen Co., Ltd.
Timeline
Phase 2Not Yet Recruiting
202420252026
Enrollment StartAug 2023
First PostedAug 2023
Primary CompletionAug 2025
TodayJul 2026
Study CompletionAug 2026
First PostedAug 18, 2023
Enrollment StartAug 1, 2023
Primary CompletionAug 1, 2025
Study CompletionAug 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 2.9 years ago
Interventions
RC48-ADCdrug
Patients are treated with RC48-ADC at 2.0 mg/kg as an intravenous infusion over 30-90 minutes (60 minutes is recommended) once every 2 weeks for 12 weeks.